NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced an expanded partnership with WuXi Clinical Development Services (“WuXi CDS”), a wholly-owned subsidiary of the global pharmaceutical, biopharmaceutical and medical device open-access capability and technology platform company, WuXi AppTec.
WuXi CDS is standardizing on the Medidata Clinical Cloud® to enhance its capabilities in early-phase and bioequivalence (BE) studies, bringing operational efficiencies to its customers’ clinical development programs across the country.
“WuXi CDS’ strengthened partnership with Medidata reinforces our commitment to advancing the scientific goals of our customers—both big and small, global and local,” said Mr. Jinjin Liang, Vice President, Head of WuXi Clinical Development Services. “Medidata’s agile, globally-validated platform is enabling our study teams to conduct insightful and value-driven clinical research in a timely manner—ultimately helping us serve the needs of our clients to bring innovative, breakthrough products to the Chinese market. We’re excited about taking our R&D programs to the next level, and look forward to entering a long-term strategic relationship with Medidata.”
WuXi CDS offers comprehensive Phase I–IV clinical development services for pharmaceutical, biologic and medical devices companies in China and abroad. In increasing its adoption of Medidata Rave®, the industry’s leading cloud-based technology for electronic data capture (EDC), management and reporting, WuXi will provide more flexible, customized strategic solutions to advance the development of new therapies across a number of therapeutic areas, including: oncology, immunology, infectious diseases, respiratory, gastroenterology, hematology, cardio-metabolic, dermatology and gynecology. WuXi has also recently become accredited in Medidata’s randomization and trial supply management solution (Medidata Balance®), which it is leveraging on an increasing number of domestic studies.
“We are thrilled to be working with WuXi CDS, a company that is uniquely positioned to bring highly specialized clinical expertise and deep local knowledge to both the global and Chinese market,” said Edwin Ng, Medidata’s vice president of field operations, APeJ (Asia Pacific except Japan). “At Medidata, we share WuXi CDS’ vision of conducting high quality clinical research, and we’re proud that our robust, cutting-edge technology is playing a key role in supporting the organization’s strong portfolio of clinical studies for today’s most prevalent illnesses.”
Mike Capone, Medidata’s chief operating officer, added: “Medidata is proudly working with more than 100 CROs, as well as services, consulting and technical partners, to help sponsors realize the value and powerful new insights that technology and data analytics can bring to their clinical trials. WuXi is a market leader and a strong agent of change for the global life sciences industry, and we’re committed to further supporting the team’s efforts to accelerate promising new drug compounds, biologics and medical devices for its clients and their patients everywhere.”
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@WuXi_AppTec #ClinicalDevelopment Services selects #MedidataRave for streamlined #datacapture & study ops http://ow.ly/DEOj30b7WHZ @Medidata
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About WuXi Clinical Development Services
WuXi Clinical Development Services is a wholly-owned subsidiary of WuXi AppTec in China. The company offers comprehensive Phase I – IV clinical development services for pharmaceuticals, biologics, and medical devices. WuXi CDS specializes in helping bring innovative, breakthrough products to market – a process that demands stringent quality control and experienced professionals from Phase I through to final submission.
WuXi CDS also offers flexible, customized strategic solutions – professionals who deliver services right from the clients’ offices, supporting specific tasks or helping ride out the peaks and troughs inherent in clinical development project timelines.
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies and is used by 16 of the top 20 medical device developers—from study design and planning through execution, management and reporting.